Zomedica (ZOM) said Monday that it has launched two new canine assays for its Truforma in-clinic biosensor testing platform.
One of the tests detects NT-proBNP in dogs, an indication of conditions such as congestive heart failure, the company said.
Another is used to detect progesterone levels, which can be used to determine optimal breeding dates, timing cesarean sections, and detecting reproductive disorders, the company said.
The test delivery results are available in less than 20 minutes, the company said,
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。